Shire (pharmaceutical company) explained

Shire plc
Predecessor:Shire Pharmaceuticals Group Plc
Type:Subsidiary[1]
Traded As:NASDAQ:
Fate:Acquired by Takeda
Industry:Pharmaceuticals
Key People:Flemming Ornskov (CEO)
Thomas Dittrich (CFO)
Location:Massachusetts,United States[2] [3]
Revenue:$15,160.6 million (2017)[4]
Operating Income:$2,455.2 million (2017)
Net Income:$4,271.5 million (2017)
Num Employees:23,044 (2018)[5]
Parent:Takeda Pharmaceutical Company (2019)
Homepage:www.shire.com

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products were available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.

The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices are located in Dublin, Ireland, the United States in Cambridge, Massachusetts, and Chicago, Illinois, and in Zug, Switzerland. In addition, Shire owns manufacturing sites in Lexington, Massachusetts, and Social Circle, Georgia. Shire's headquarters in Lexington, Massachusetts, will be integrated with Takeda's new U.S. headquarters, which is being relocated from Deerfield, Illinois, to the Boston area.

History

Early history

Shire was founded in 1986 in the UK by five entrepreneurs: Harry Stratford, Dennis Stephens, Peter Moriarty, Geoff Hall and Dr Jim Murray.[6] Under the management of Rolf Stahel, Shire was first listed on the London Stock Exchange in 1996. Shire's initial products were calcium supplements (Calcichew-D3) for patients seeking to treat or prevent osteoporosis. In 1997 the company acquired Pharmavene for £105 million in order to access Pharmavene's drug delivery methods.[7] Later in the same year Shire acquired Richwood Pharmaceutical Company, forming Shire-Richwood Inc.[8]

2000 to 2009

In 2001 the company acquired Biochem Canada.[9] Shire's next acquisition didn't come until 2005 when it acquired Transkaryotic Therapeutics[10] and two years later – in 2007 – New River Pharmaceuticals Inc, for a then company record of $2.6 billion.[11] With the purchase of New River, Shire gained access and ownership of Vyvanse. A year later the company acquired the German company Jerini, for $521 million. Jerini focused on treating hereditary angioedema.[12]

In 2008, in reaction to new taxation measures announced by the UK government in the treatment of royalties on patents, the company moved its tax domicile to Dublin, Ireland.[13]

2010 onwards

2010 saw a change in company strategy, with the company seeking to expand through mergers and acquisitions - culminating in the company becoming one of the most acquisitive in the industry. In 2010 the company acquired Movetis, a Belgian company focusing on gastrointestinal products for $565 million,[14] a year later it acquired regenerative medicine manufacturer Advanced BioHealing.[15] In 2012 the company acquired FerroKin BioSciences for $325 million along with FerroKins lead iron chelator - FBS0701.[16] 2013 saw the company complete its highest number of acquisitions with Lotus Tissue Repair, Inc. (lead compound, ABH001),[17] SARcode Bioscience Inc.,[18] with the last being ViroPharma. Shire changed the name of ViroPharma to Shire Viropharma Inc. upon acquisition and on their final day of trading the company was valued at $3.3 billion.[19] At $4.2 billion, ViroPharma set a new company record.[20] In 2014 Shire acquired two rare disease drug companies: Fibrotech[21] with its antifibrotic compounds for $75 million, and Lumena, a company researching rare gastro-intestinal and hepatic compounds, for $260 million.[22]

In 2015, NPS Pharmaceuticals was acquired for $5.2 billion, bringing along its rare disease drugs Gattex and Natpara.[23] On their final day of trading, NPS had a market capitalisation of $4.99 billion. The company also acquired, later in the same year, Meritage Pharma for $245 million, Foresight Biotherapeutics for $300 million[24] and Dyax for $6.5 billion.[25] [26] The purchases bolstered Shires gastro-intestinal and rare disease sectors, with Phase-III-ready treatment - Budesonide - for the treatment of eosinophilic esophagitis. As well as expanding the company's pipeline with a late-stage treatment candidate for infectious conjunctivitis with lead candidate FST-100 and increasing the company's rare disease catalogue with Dyax's portfolio of plasma kallikrein inhibitors against hereditary angioedema (led by the approved drug Kalbitor and the Phase III DX-2930). In January 2016, the company made its most significant purchase, with the $32 billion acquisition of Baxalta (which had been spun-off from Baxter the previous year[27]), creating the largest global biotech company focused solely on rare diseases.[28]

In April 2018, Shire agreed to sell its oncology business to French pharmaceutical company Servierfor £1.7billion.[29]

Aborted AbbVie takeover

On 20 June 2014, Shire rejected a takeover attempt by AbbVie. AbbVie offered £46.11 per share (£27.3 billion or $46.5 billion in total).[30] On 8 July, the offer was increased to $51.5 billion.[31] On 18 July, it was announced that AbbVie would acquire Shire for $54.8 billion.[32] On 15 October, news broke suggesting AbbVie was reconsidering their proposed takeover deal due to changes in US "Tax Inversion" law[33] and on 16 October AbbVie's board recommended that shareholders vote against the deal.[34] This news sent Shire's share price down over 27%; however, AbbVie would be subject to a $1.6 billion break-up fee, payable to Shire.[35] On 21 October, the merger was called off.[36]

Takeda takeover

In April 2018, reported that Takeda Pharmaceutical Company had an approach to acquire Shire. Days later Shire announced they had rejected all three Takeda bids. The first bid valued the business at £41 billion (£28 per Shire shares paid in Takeda shares plus £16 per share in cash), the second £43 billion (£28.75 per Shire shares paid in Takeda shares plus £16.75 per share in cash) and the third £44 billion (£28 per Shire shares paid in Takeda shares plus £17.75 per share in cash).[37] Reuters also reported interest from Allergan[38] however they ruled themselves out a day later.[39] A day later Takeda increased their offer with a fourth bid, to £26 per Shire shares paid in Takeda shares plus £21 per share in cash - giving a total value of £44.3 billion ($62.1 billion).[40] On 24 April, Takeda submitted an enhanced fifth bid for the company.[41] On 25 April, Shire said that they will recommend the revised £45.8 billion ($64 billion) offer to their shareholders. The enhanced offer included a more generous cash component, with the deal offering £21.76 ($30.33) in cash for each Shire ordinary share.[42] [43] [44] The same day, GlaxoSmithKline ruled out making any form of counter-bid.[45] On 8 May 2018, an agreement was finally reached in which Shire was sold to Takeda in a $62 billion deal.[46] [47] Takeda's acquisition of Shire closed on 8 January 2019.[48]

Acquisition history

Products

The Annual Revenue figures in the following table were drawn from the company's 2015 preliminary results.[49]

NameAnnual revenueIndication
Vyvanse$1,722MAttention deficit hyperactivity disorder (ADHD)
Lialda/Mezavant$684MGastrointestinal (ulcerative colitis)
Cinryze$618MSwelling attacks in children
Gattex/Revestive & Natpara$166MShort Bowel Syndrome (SBS) & hypocalcemia in patients with hypoparathyroidism
Firazyr$445MHereditary angioedema
Replagal$441MFabry Disease (α-galactosidase A deficiency)
Adderall XR$362MAttention deficit hyperactivity disorder (ADHD)
Vpriv$342MType 1 Gaucher disease

Licences & Royalties

In July 2014, Shire licensed the rights to the investigational Hunter syndrome compound, AGT-182, from ArmaGen for up to $225 million.[50]

The Annual Revenue figures in the following Table were drawn from the company's 2015 preliminary results.[49]

NameAnnual revenueIndicationLicensee
Adderall XR$70.3MAttention deficit hyperactivity disorder (ADHD)Impax and Teva
$91.6MHIV and Chronic hepatitis BGlaxoSmithKline
Fosrenol$53.3MRenal diseaseBayer Yakuhin
Other$26.4M

Corporate leadership

Flemming Ørnskov, was the company's chief executive officer through 8 January 2019 with Takeda's acquisition of Shire.[51] Ginger Gregory as chief human resources officer, Jeffrey Poulton as CFO, and Philip Vickers as head of R&D.[52] James Bowling vacated his position as interim CFO in the aftermath of the collapse of the AbbVie inversion deal.[53] The chair of Shire's board of directors was Susan Kilsby.[54]

Legal issues

False Claims Act violations

In September 2014, Shire reached a $56.5 million settlement with the U.S. Department of Justice for alleged violations of the False Claims Act. The Justice Department alleged that Shire had improperly marketed and promoted Adderall XR, Daytrana, Vyvane, Pentasa, and Lialda during various periods between 2004 and 2010. The allegations included claims that Shire had made exaggerated and false statements regarding product safety, promoted medications for non-FDA approved off-label use, and marketed products on unsubstantiated claims of beneficial side effects, including reductions in criminality, traffic accidents, sexually transmitted infections, and divorce rates.[55] [56] [57]

Illegal promotion of Dermagraft

In August 2017, Shire reached a $350 million settlement with the Department of Justice for violations of the same act, regarding the unlawful promotion of Shire's product Dermagraft.[58] [59]

See also

Notes and References

  1. Web site: Takeda completes buyout of Shire to become top 10 global pharmaceutical firm. 8 January 2019. 22 February 2021. 26 February 2021. https://web.archive.org/web/20210226072400/https://www.japantimes.co.jp/news/2019/01/08/business/corporate-business/takeda-completes-buyout-shire-become-top-10-global-pharmaceutical-firm/. live.
  2. Web site: Takeda closes $62B purchase of Shire, creating largest Mass. biotech employer . Allison . DeAngelis . Boston Business Journal . January 7, 2019 . 24 February 2021 . 28 February 2022 . https://web.archive.org/web/20220228190658/https://www.bizjournals.com/boston/news/2019/01/07/takeda-closes-62b-purchase-of-shire-creating.html . live .
  3. Web site: Contact us | Takeda Pharmaceuticals U.S.A., Inc. 24 February 2021. 25 February 2021. https://web.archive.org/web/20210225113031/https://www.takeda.com/en-us/who-we-are/contact-us. live.
  4. Web site: Preliminary Results 2017. Shire. 17 March 2018. 17 March 2018. https://web.archive.org/web/20180317165148/https://www.shire.com/-/media/shire/shireglobal/shirecom/pdffiles/newsroom/2018/full-year-2017-results.pdf. live.
  5. Web site: Shire Company Profile. craft.co. 8 October 2019. 8 October 2019. https://web.archive.org/web/20191008095349/https://craft.co/shire. live.
  6. Web site: Shire is one of the big stars. https://web.archive.org/web/20160406171245/http://www.thesundaytimes.co.uk/sto/business/Industry/article830604.ece. dead. 6 April 2016. Sunday Times. 27 November 2011. 26 March 2016.
  7. Web site: Shire buys US drugs delivery firm for pounds 105m. Grimond, Magnus. 1997-02-26. The Independent. 22 March 2016. 4 March 2016. https://web.archive.org/web/20160304195656/http://www.independent.co.uk/news/business/shire-buys-us-drugs-delivery-firm-for-pounds-105m-1280736.html. live.
  8. Web site: Investment Column: Shire focuses on buying Richwood. Grimond, Magnus. 1997-08-04. The Independent. 22 March 2016. 5 March 2016. https://web.archive.org/web/20160305002411/http://www.independent.co.uk/news/business/investment-column-shire-focuses-on-buying-richwood-1243915.html. live.
  9. Web site: Canadians give go-ahead for Shire takeover of BioChem. Dunne, Helen. 2001-05-10. Telegraph.co.uk. 22 March 2016. 28 February 2016. https://web.archive.org/web/20160228075658/http://www.telegraph.co.uk/finance/2717558/Canadians-give-go-ahead-for-Shire-takeover-of-BioChem.html. live.
  10. News: Shire to Buy Transkaryotic Therapies for $1.6 Billion. 29 April 2005. FDA News. 17 April 2022.
  11. Web site: Shire buys New River Pharmaceuticals for $2.6 billion. pharmatimes.com. 22 March 2016. https://web.archive.org/web/20160310141245/http://pharmatimes.com/mobile/07-02-21/shire_buys_new_river_pharmaceuticals_for_2_6_billion.aspx. 10 March 2016. dead. dmy-all.
  12. Web site: Shire to buy Jerini in $521M deal. FierceBiotech. 3 July 2008 . 22 March 2016. 6 April 2016. https://web.archive.org/web/20160406121213/http://www.fiercebiotech.com/story/shire-buy-jerini-521m-deal/2008-07-03. live.
  13. http://www.irishexaminer.com/archives/2008/0416/business/shire-moves-to-ireland-for-tax-60386.html Shire moves to Ireland for tax
  14. Web site: Shire forges $565M buyout deal for Movetis. FierceBiotech. 3 August 2010 . 22 March 2016. 4 March 2016. https://web.archive.org/web/20160304060231/http://www.fiercebiotech.com/story/shire-forges-565m-buyout-deal-movetis/2010-08-03. live.
  15. Web site: Grogan, Kevin . 2011-05-18 . Shire swoops to buy Advanced BioHealing . pharmatimes.com . 22 March 2016 . https://web.archive.org/web/20160307081033/http://pharmatimes.com/article/11-05-18/shire_swoops_to_buy_advanced_biohealing.aspx . 7 March 2016 . dead . dmy-all .
  16. Web site: Shire to buy U.S. biotech firm for up to $325 million. Reuters Editorial. 15 March 2012. Reuters. 22 March 2016. 8 March 2016. https://web.archive.org/web/20160308084150/http://www.reuters.com/article/us-shire-idUSBRE82E0K520120315. live.
  17. Web site: Shire Acquires Lotus Tissue Repair. 8 January 2013. GEN. 26 March 2016. 13 April 2016. https://web.archive.org/web/20160413005551/http://www.genengnews.com/gen-news-highlights/shire-acquires-lotus-tissue-repair/81247840/. live.
  18. News: Shire to Buy Eye-Drug Maker SARcode for $160 Million. Bloomberg.com. 25 March 2013. Bloomberg. 26 March 2016. 7 April 2016. https://web.archive.org/web/20160407162525/http://www.bloomberg.com/news/articles/2013-03-25/shire-to-buy-eye-drug-maker-sarcode-for-160-million. live.
  19. News: Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug. Bloomberg.com. 11 November 2013. Bloomberg. 26 March 2016. 19 March 2016. https://web.archive.org/web/20160319154957/http://www.bloomberg.com/news/articles/2013-11-11/shire-agrees-to-buy-viropharma-for-about-4-2-billion-1-. live.
  20. News: Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug. Trista Kelley. Makiko Kitamura. amp. 11 November 2013. Bloomberg.com. 22 March 2016. 11 January 2015. https://web.archive.org/web/20150111154751/http://www.bloomberg.com/news/2013-11-11/shire-agrees-to-buy-viropharma-for-about-4-2-billion-1-.html. live.
  21. Web site: Fibrotech acquired by Shire for US$75M plus milestones. FierceBiotech. May 2014 . 23 September 2014. 17 July 2014. https://web.archive.org/web/20140717045105/http://www.fiercebiotech.com/press-releases/fibrotech-acquired-shire-us75m-plus-milestones. live.
  22. Web site: GEN - News Highlights:Shire Acquires Lumena for $260M+. GEN. 12 May 2014. 2 June 2014. 2 June 2014. https://web.archive.org/web/20140602195942/http://www.genengnews.com/gen-news-highlights/shire-acquires-lumena-for-260m/81249851/. live.
  23. News: UK drug firm Shire to buy US rival in $5.2bn deal. BBC News. 11 January 2015. 22 March 2016. 17 February 2016. https://web.archive.org/web/20160217172111/http://www.bbc.co.uk/news/business-30772280. live.
  24. Web site: Shire Acquires Foresight Biotherapeutics for $300M. GEN. 3 August 2015. 22 March 2016. 6 April 2016. https://web.archive.org/web/20160406063026/http://www.genengnews.com/gen-news-highlights/shire-acquires-foresight-biotherapeutics-for-300m/81251584. live.
  25. Web site: Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period - Business Wire. 2 December 2015. businesswire.com. 22 March 2016. 4 March 2016. https://web.archive.org/web/20160304103802/http://www.businesswire.com/news/home/20151202006452/en/. live.
  26. Web site: Shire to Acquire Dyax for Up to $6.5B. GEN. 2 November 2015. 22 March 2016. 19 March 2016. https://web.archive.org/web/20160319231525/http://www.genengnews.com/gen-news-highlights/shire-to-acquire-dyax-for-up-to-6-5b/81251922/. live.
  27. Web site: Baxter's Board of Directors Approves Separation of Baxalta and Declares Special Dividend of Baxalta Stock. investor.baxter.com. Baxter International Inc.. 15 January 2017. 6 May 2017. https://web.archive.org/web/20170506115815/http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-newsArticle&ID=2056943. live.
  28. Web site: Shire, Baxalta Tie the Knot in $32B Merger. GEN. 11 January 2016. 22 March 2016. 20 March 2016. https://web.archive.org/web/20160320140922/http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/. live.
  29. News: Javed. Ayesha. Shire sells oncology unit for £1.7bn as Takeda boss prepares potential bid. 16 April 2018. The Telegraph. 16 April 2018. 16 April 2018. https://web.archive.org/web/20180416104240/https://www.telegraph.co.uk/business/2018/04/16/shire-sells-oncology-unit-17bn-takeda-boss-prepares-potential/. live.
  30. News: AbbVie Said to Consider New Bid After Shire Rejects Offer. David Welch, Matthew Campbell. Simeon Bennett. amp. 21 June 2014. Bloomberg. 11 March 2017. 12 January 2015. https://web.archive.org/web/20150112093844/http://www.bloomberg.com/news/2014-06-20/abbvie-offered-46-5-billion-for-shire-as-bid-rejected.html. live.
  31. Web site: AbbVie Raises Offer for Shire to $51.5 Billion. Caroline Chen, Drew Armstrong. Simeon Bennett. amp. 8 July 2014. Bloomberg. 11 March 2017. 8 January 2015. https://web.archive.org/web/20150108135743/http://www.bloomberg.com/news/2014-07-08/abbvie-raises-offer-for-shire-to-51-5-billion.html. live.
  32. Web site: AbbVie Is Biggest to Quit U.S. Address in $55 Billion Shire Deal. Simeon Bennett. Caroline Chen. amp. 19 July 2014. Bloomberg. 11 March 2017. 12 January 2015. https://web.archive.org/web/20150112093835/http://www.bloomberg.com/news/2014-07-18/abbvie-to-buy-shire-for-54-8-billion-as-drug-deals-surge.html. live.
  33. Web site: AbbVie Reconsidering Shire Sends Inversion Targets Down. Albertina Torsoli, Kristen Hallam. Oliver Staley. amp. 15 October 2014. Bloomberg. 11 March 2017. 11 January 2015. https://web.archive.org/web/20150111175627/http://www.bloomberg.com/news/2014-10-15/abbvie-reconsidering-shire-sends-inversion-targets-down.html. live.
  34. Web site: AbbVie Board Recommends Holders Vote Against Shire Deal. Albertina Torsoli, Manuel Baigorri. Matthew Campbell. amp. 16 October 2014. Bloomberg. 11 March 2017. 12 January 2015. https://web.archive.org/web/20150112225553/http://www.bloomberg.com/news/2014-10-15/abbvie-said-close-to-shire-reversal-as-tax-rules-change.html. live.
  35. Web site: Shire Shares Extend Drop After AbbVie Backtracks on Deal. Albertina Torsoli, Manuel Baigorri. Matthew Campbell. amp. 16 October 2014. Bloomberg. 11 March 2017. 9 January 2015. https://web.archive.org/web/20150109225233/http://www.bloomberg.com/news/2014-10-16/abbvie-board-recommends-holders-vote-against-shire-deal.html. live.
  36. News: AbbVie, Shire Call Off $51.7B Merger . . GEN News Highlights . 21 October 2014 . Philippidis, Alex . 22 October 2014 . 24 October 2014 . https://web.archive.org/web/20141024021248/http://www.genengnews.com/gen-news-highlights/abbvie-shire-call-off-51-7b-merger/81250493 . live .
  37. Web site: Statement re Proposal from Takeda Pharmaceutical Company Limited. www.shire.com. 19 April 2018. 20 April 2018. https://web.archive.org/web/20180420060506/https://www.shire.com/en/newsroom/2018/april/mdt9go. live.
  38. News: Shire rejects $63 billion Takeda bid as Allergan drops pursuit. Greg. Roumeliotis. Reuters. 20 April 2018. 19 April 2018. 19 April 2018. https://web.archive.org/web/20180419182753/https://uk.reuters.com/article/us-shire-m-a-takeda-pharma-bid/allergan-moves-in-as-shire-rebuffs-63-billion-takeda-bid-sources-idUKKBN1HQ1PN. live.
  39. News: Exclusive - Allergan in talks to acquire Shire, competing against.... Reuters. Editorial. Reuters. 19 April 2018. 19 April 2018. 19 April 2018. https://web.archive.org/web/20180419165610/https://uk.reuters.com/article/uk-shire-m-a-allergan-exclusive/exclusive-allergan-in-talks-to-acquire-shire-competing-against-takeda-sources-idUKKBN1HQ218. live.
  40. News: Japan's Takeda sweetens $62 billion Shire offer. Sam. Nussey. Reuters. 20 April 2018. 20 April 2018. 20 April 2018. https://web.archive.org/web/20180420183204/https://uk.reuters.com/article/us-shire-m-a-takeda/japans-takeda-nudges-up-shire-offer-to-47-pounds-a-share-idUKKBN1HR00T. live.
  41. News: Shire willing to back $64 billion Takeda bid, market signals doubts. Ben. Martin. Reuters. 25 April 2018. 24 April 2018. 24 April 2018. https://web.archive.org/web/20180424144721/https://uk.reuters.com/article/uk-shire-m-a-takeda-pharma/shire-receives-new-bid-from-takeda-as-takeover-deadline-looms-idUKKBN1HV1FY. live.
  42. News: Shire backs Takeda's £46bn offer. 25 April 2018. BBC News. 22 June 2018. 28 April 2018. https://web.archive.org/web/20180428044659/http://www.bbc.co.uk/news/business-43889437. live.
  43. News: Shire willing to back $64 billion Takeda bid, market signals doubts. Ben. Martin. Reuters. 25 April 2018. 25 April 2018. 25 April 2018. https://web.archive.org/web/20180425111811/https://uk.reuters.com/article/uk-shire-m-a-takeda-pharma-deal-exclusiv/shire-willing-to-back-64-billion-takeda-bid-market-signals-doubts-idUKKBN1HV2OQ. live.
  44. News: Shire bid marks Takeda's latest - and biggest - push for global status. Sam. Nussey. Reuters. 25 April 2018. 25 April 2018. 25 April 2018. https://web.archive.org/web/20180425154714/https://uk.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUKKBN1HW11A. live.
  45. News: GSK rules out entering Shire takeover battle. Reuters. Editorial. Reuters. 25 April 2018. 25 April 2018. 25 April 2018. https://web.archive.org/web/20180425121509/https://uk.reuters.com/article/us-shire-m-a-takeda-pharma-gsk/gsk-rules-out-entering-shire-takeover-battle-idUKKBN1HW1JT. live.
  46. News: Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire. Bloomberg.com. 2018-05-08. en. 8 May 2018. https://web.archive.org/web/20180508090835/https://www.bloomberg.com/news/articles/2018-05-08/takeda-inks-62-billion-deal-to-buy-shire-for-cash-and-shares. live.
  47. News: Japan's Takeda agrees $62 billion takeover of Shire. Reuters Editorial. U.S.. 2018-05-08. en-US. 8 May 2018. https://web.archive.org/web/20180508101816/https://www.reuters.com/article/us-shire-m-a-takeda/japans-takeda-agrees-62-billion-takeover-of-shire-idUSKBN1I90IC. live.
  48. Web site: Takeda completes Shire acquisition. 8 January 2019. Pharma Times. 24 January 2019. 11 January 2019. https://web.archive.org/web/20190111224604/http://www.pharmatimes.com/news/takeda_completes_shire_acquisition_1274243. live.
  49. Web site: Preliminary Results 2015. Shire. 26 March 2016. 6 April 2016. https://web.archive.org/web/20160406192344/http://investors.shire.com/~/media/Files/S/Shire-IR/quarterly-reports/2016/full-year-2015-results-press-release.pdf. live.
  50. Web site: GEN - News Highlights:ArmaGen Licenses AGT-182 Rights to Shire for Up to $225M. GEN. 23 July 2014. 24 July 2014. 27 July 2014. https://web.archive.org/web/20140727194522/http://www.genengnews.com/gen-news-highlights/armagen-licenses-agt-182-rights-to-shire-for-up-to-225m/81250142/?kwrd=Shire. live.
  51. News: Bennett, Simeon . Shire's New CEO Adds Sales Staff, Damps Takeover Talk . 2013-06-10 . . 22 March 2016 . 3 April 2016 . https://web.archive.org/web/20160403210413/http://www.bloomberg.com/news/articles/2013-06-10/shire-s-new-ceo-adds-sales-staff-damps-takeover-talk . live .
  52. Web site: Shire Staff . 2016-03-22 . Leadership: Executive Committee . Shire . 13 February 2015 . 15 June 2015 . https://web.archive.org/web/20150615002413/https://www.shire.com/who-we-are/leadership/executive-committee . live .
  53. News: Schaps, Karolin . Hirschler, Ben . amp . 2014-10-20 . Shire CFO to leave drugmaker as AbbVie drops bid . . 22 March 2016 . 4 April 2016 . https://web.archive.org/web/20160404120049/http://www.reuters.com/article/us-shire-moves-cfo-idUSKCN0I90M720141020 . live .
  54. Web site: Shire Staff . 2016-03-22 . Leadership: Board of Directors . Shire . 22 March 2016 . 25 March 2016 . https://web.archive.org/web/20160325071238/https://www.shire.com/who-we-are/leadership/board-of-directors . live .
  55. Web site: Shire Pays $56.5M to Settle False-Claims Whistleblower Suit . Genetic Engineering & Biotechnology News . 25 September 2014 . 27 November 2021 . 27 November 2021 . https://web.archive.org/web/20211127215210/https://www.genengnews.com/news/shire-pays-56-5m-to-settle-false-claims-whistleblower-suit/ . live .
  56. Web site: Shire Pharmaceuticals LLC to Pay $56.5 Million to Resolve False Claims Act Allegations Relating to Drug Marketing and Promotion Practices . The United States Department of Justice . 24 September 2014 . Office of Public Affairs . 27 November 2021 . 27 November 2021 . https://web.archive.org/web/20211127215403/https://www.justice.gov/opa/pr/shire-pharmaceuticals-llc-pay-565-million-resolve-false-claims-act-allegations-relating-drug . live .
  57. Web site: Adderall Maker to Pay $56.5 Million to Resolve False Claims Charge . Corporate Crime Reporter . 25 September 2014 . 27 November 2021 . 27 November 2021 . https://web.archive.org/web/20211127215551/https://www.corporatecrimereporter.com/news/200/adderall-maker-pay-56-5-million-resolve-false-claims-charge/ . live .
  58. Web site: Pharmaceutical company agrees to 'landmark' settlement in Tampa federal court . The Business Journals . 27 November 2021 . 14 January 2017 . https://web.archive.org/web/20170114120445/http://www.bizjournals.com/tampabay/news/2017/01/11/pharmaceutical-company-agrees-to-landmark.html . live .
  59. News: U.S. says Shire subsidiaries to pay $350 million to settle false claims act allegations . Reuters . 11 January 2017 . 27 November 2021 . 27 November 2021 . https://web.archive.org/web/20211127224523/https://www.reuters.com/article/us-shire-usa-idUKKBN14V1WS . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Shire (pharmaceutical company)".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.